Syngene International
Syngene International is recorded as a service provider in 32 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 20 of 32 trials · Latest update first
A Phase 2 Randomized, Double-blind, Placebo‑controlled, Dose‑ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Subjects With Type 2 Diabetes Mellitus
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
A randomized, placebo-controlled, parallel group, 72-week study to evaluate the efficacy and safety of VHB937 in participants with early Alzheimer’s Disease followed by an Extension
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Open-Label, Multicenter, Randomized Study of Subcutaneous vs Intravenous Tarlatamab in Participants with Relapsed Extensive-Stage Small Cell Lung Cancer After Platinum-based First-line chemotherapy (DeLLphi-315)
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab versus Placebo for Participants with Hepatocellular Carcinoma Who Are at High Risk of Recurrence after Curative Hepatic Resection or Ablation (CheckMate 9DX: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 9DX)
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OASIS PEDIATRIC [EM])
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Rerandomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASTRO)
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available8 trial-level findings · Read insights
- The protocol specified that both co-primary endpoints had to achieve statistical significance to declare trial success.
- Participants achieving vIGA-AD 0/1 and/or EASI-75 at Week 24 without atopic-dermatitis rescue therapy continued into blinded maintenance with re-randomization to every-4-week or every-8-week dosing.
- Eligibility was updated to require at least 12 months of atopic dermatitis before consent and an EASI score of at least 16 at initial screening.
- Participants previously treated systemically for atopic dermatitis could be eligible after an appropriate washout because they were considered inadequate responders to topical treatments.
- Tuberculosis eligibility was clarified to allow a positive or indeterminate QuantiFERON test after adequate completed prophylaxis, absent tuberculosis symptoms, new exposure, or radiographic evidence of active disease.
- The protocol added cardiovascular exclusions, including New York Heart Association class III/IV heart failure, uncontrolled hypertension, inadequately treated cardiovascular conditions, and recent cardiovascular events.
- Rescue-therapy rules were updated to require temporary interruption or permanent discontinuation of investigational product according to systemic corticosteroid duration and use of specified systemic therapies or topical JAK inhibitors.
- Patient-reported outcome assessments using DLQI/CDLQI were clarified for participants aged 12 years or older and those younger than 12 years.
These findings describe the trial, not the service provider’s performance or responsibility.
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein (a)
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2 Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants with Advanced Solid Tumors
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Phase 3, 24-week, Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Ignite)
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- The trial was conducted at 168 centers across Europe, Asia, North America, and Latin America from May 2022 to January 2025.
- A protocol amendment increased the anticipated sample size by approximately 100 participants, from 400 to 500, to meet country-specific enrollment requirements.
- Nine participants from US sites were excluded from all efficacy and safety analyses: two were enrolled under the original 52-week every-2-week regimen and seven were associated with a site-wide serious breach and GCP violations.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Combination With Topical Corticosteroids and/or Topical Calcineurin Inhibitors in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-SHUTTLE)
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
Operational learnings available3 trial-level findings · Read insights
- The trial was conducted at 180 centers across Europe, North America, Asia, Latin America, and Oceania between February 2023 and December 2024.
- A substantial protocol amendment required atopic dermatitis to have been diagnosed at least 6 months before informed consent.
- A substantial protocol amendment clarified that participants previously treated systemically for atopic dermatitis could be eligible after an appropriate washout period.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND)
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects with Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment (DeLLphi-301).
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
Adjustable brodalumab dosage regimen compared with standard brodalumab treatment for 52 weeks in subjects with moderate-to-severe plaque psoriasis and ≥120 kg body weight; ADJUST - Phase 4 – efficacy, A randomised, double-blind, controlled, parallel group, multi-centre trial
Sponsor Leo Pharma A/S
- Start (EU)
- Latest update
- Estimated end
A Double-blind, Randomized,Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants with Elevated Lipoprotein(a)
Sponsor Amgen Inc.
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 3, Open-label, Multicenter, Randomized Study of Tarlatamab in Combination with Durvalumab vs Durvalumab Alone in Subjects with Extensive Stage Small Cell Lung Cancer Following Platinum, Etoposide and Durvalumab (DeLLphi 305)
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
A three-period multicenter study, with a randomized-withdrawal, double-blinded, placebo-controlled design to evaluate the clinical efficacy, safety and tolerability of MAS825 in patients with monogenic IL-18 driven autoinflammatory diseases, including NLRC4-GOF, XIAP deficiency, or CDC42 mutations.
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in combination with Durvalumab, Carboplatin and Etoposide versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
CA209-9DW - A Randomized, Multi-center, Phase 3 Study of Nivolumab in Combination with Ipilimumab Compared to Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma
Sponsor Bristol-Myers Squibb Services Unlimited Company
- Start (EU)
- Latest update
- Estimated end
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS SCLC) who Have not Progressed Following Concurrent Chemoradiation Therapy (DeLLphi-306)
Sponsor Amgen Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Syngene International?
The 2026-10-09 snapshot links Syngene International to 32 distinct CTIS trials. Recorded services include Laboratory services, T-cell phenotyping, PK and ADA analysis, Genetic/Genomic analysis, among 9 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Syngene International?
The most frequently recorded therapeutic areas are Dermatology, Immunology, Solid Tumor Oncology, Neurology. Recorded phases include Phase 3, Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Syngene International conducted?
The linked trials record locations in 26 countries, including Germany, Spain, Italy, Poland, Belgium. These are trial locations, not confirmed office locations or countries where Syngene International delivered services.
What can this page tell me about Syngene International's trial experience?
Browse 32 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 3 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Syngene International. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Syngene International Limited